Girentuximab companion diagnostic - Heidelberg Pharma/Nuclea Biotechnologies
Alternative Names: CAIX Dx; CAIX ELISA/IHC testLatest Information Update: 28 Jul 2018
At a glance
- Originator Oncogene Science; WILEX AG
- Developer Heidelberg Pharma AG; Nuclea Biotechnologies
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Renal cell carcinoma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Renal-cell-carcinoma(Diagnosis) in USA
- 06 Sep 2013 Nuclea Biotechnologies acquires Wilex Oncogene Science
- 11 Jul 2013 Clinical trials in Renal cell carcinoma (diagnosis) in USA (in vitro)